Novaroche: Novartis' Very Swiss Bid for Roche
With pharma consolidation, it sometimes seems, all things are possible. At least that's what Novartis hopes. The giant Swiss firm's surprise purchase of 20% of the voting shares of Roche is, in many ways, a typically Swiss transaction. In accordance with the clubby and personal nature of Swiss big business, the deal was privately negotiated. But it also makes intrinsic financial sense from tax, share-price, and synergies points of view.
You may also be interested in...
The use of virtual, real-time and at-home testing to provide clinical trials data has been steadily gaining the interest of the health care industry. COVID-19 has put this opportunity into sharper focus, says CNS trials technology developer Cambridge Cognition, which is now adding a voice option to its portfolio.
Device financing totaled $1.4bn during the first quarter of 2020. Merger and acquisition activity reached $714.5m, with only two transactions hitting the six-figure mark. Financings by diagnostics/research players totaled $985m and just six companies were acquired, four of which together were valued at $11.6bn, most coming from Thermo Fisher Scientific’s $11.5bn buy of fellow public life sciences company Qiagen NV.
A selection of features you might have missed from the first six months of 2020, covering key topics from COVID-19 strategies in medtech to an analysis of pipeline focus areas across the pharma sector. Click on each section to get the full story behind the data.